Public Profile

Cephalon, Inc.

Cephalon, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States and operates extensively across North America and Europe. Founded in 1987, the company has achieved significant milestones, including its acquisition by Teva Pharmaceutical Industries in 2011, which bolstered its market presence. Specialising in innovative treatments for neurological disorders, pain management, and cancer, Cephalon is renowned for its unique product offerings, such as Provigil and Nuvigil, which address sleep disorders and enhance wakefulness. With a strong commitment to research and development, Cephalon has established itself as a leader in the pharmaceutical sector, consistently delivering high-quality solutions that improve patient outcomes. Its strategic focus on niche therapeutic areas has solidified its position in the competitive biopharmaceutical landscape.

DitchCarbon Score

How does Cephalon, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

35

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Cephalon, Inc.'s score of 35 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.

0%

Let us know if this data was useful to you

Cephalon, Inc.'s reported carbon emissions

Cephalon, Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. Without emissions figures, it is challenging to assess their carbon footprint or climate commitments. However, the absence of documented reduction initiatives suggests that the company may not have established formal climate pledges or targets aligned with industry standards. As the pharmaceutical sector increasingly prioritises sustainability, it is essential for companies like Cephalon to consider implementing measurable climate strategies to enhance their environmental impact and align with global climate goals.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Cephalon, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Cephalon, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Cephalon, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Pharmacyclics LLC

US
Health and social work services (85)
Updated 3 months ago
DitchCarbon Score

Allergan, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Novartis Pharmaceuticals Corporation

US
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

INSYS Therapeutics, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Coherus BioSciences, Inc.

US
Health and social work services (85)
Updated 1 day ago

Glaxosmithkline

GB
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers